Prospective Investigation of Cardiovascular Risk Factors in Tumor Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03537339

Enrollment

500

Registered

2018-05-25

Start date

2018-03-01

Completion date

2020-12-31

Last updated

2018-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardioncology

Brief summary

In this study, prospective cohort study was used to collect the general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients who diagnosed cancer by pathology in National Cancer Center/ Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College from January 2018 to December 2020. This study intends to evaluate and screen the cardiovascular risk of tumor patients during antitumor therapy and to establish a model of cardiovascular risk assessment for tumor patients, providing clinical evidence for the prevention of cardiovascular disease risk associated with cancer patients.

Interventions

OTHERRecord general information

Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Diagnosis of malignant tumor by pathology or cytology 2. Age 18-80, KPS \> 70 3. Epidemiological information, clinical diagnosis and treatment and key information of medication are not missing. 4. The liver and kidney function were in the normal range. 5. All selected patients signed informed consent.

Exclusion criteria

1. patients diagnosed with congenital heart disease, cardiomyopathy, heart failure, arrhythmia, myocardial ischemia and myocardial infarction within 6 months before enrollment. 2. Severe impairment of liver and kidney function. 3. Left ventricular ejection fraction \< 50% by echocardiographic examination. 4. Diagnosis of more than one kind of tumor at the same time. 5. History of surgery and trauma within 3 months before enrollment. 6. Poor compliance

Design outcomes

Primary

Measure	Time frame	Description
Adverse events (AEs) related to Cardio-oncology	January 2018 to December 2020.	Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0) recorded by ECGs,UCGs and myocardial enzyme

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026